UBS Group’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,651
Closed -$104K 10939
2026
Q1
$104K Buy
3,651
+3,352
+1,121% +$97.7K ﹤0.01% 6979
2025
Q4
$8.46K Buy
+299
New +$8.44K ﹤0.01% 8359
2024
Q1
Sell
-1,340
Closed -$29K 9900
2023
Q4
$29K Sell
1,340
-230
-15% -$4.75K ﹤0.01% 6862
2023
Q3
$32K Buy
1,570
+1,439
+1,098% +$30.3K ﹤0.01% 6565
2023
Q2
$2.74K Sell
131
-995
-88% -$20K ﹤0.01% 7708
2023
Q1
$22.3K Sell
1,126
-689
-38% -$13.8K ﹤0.01% 6998
2022
Q4
$35.5K Buy
1,815
+392
+28% +$7.72K ﹤0.01% 7073
2022
Q3
$25K Buy
1,423
+335
+31% +$6.57K ﹤0.01% 7102
2022
Q2
$21K Sell
1,088
-263
-19% -$5.36K ﹤0.01% 6823
2022
Q1
$29K Sell
1,351
-526
-28% -$11.1K ﹤0.01% 7037
2021
Q4
$40K Buy
+1,877
New +$39.3K ﹤0.01% 7123

Other funds holding REVS

UBS Group's REVS Position: Q2 2026 in Review

UBS Group sold out of Columbia Research Enhanced Value ETF (REVS) in Q2 2026, closing a stake of 3,651 shares — an estimated $104K sold.

UBS Group first reported a position in REVS in Q4 2021 and held it in 11 quarters. The position peaked at $104K in Q1 2026. 37 funds tracked by Wall St. Rank hold REVS as of Q2 2026.

  • UBS Group reported no remaining Columbia Research Enhanced Value ETF position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 3,651 Columbia Research Enhanced Value ETF shares in Q2 2026, an estimated $104K.
  • UBS Group first reported a position in Columbia Research Enhanced Value ETF in Q4 2021 and held it in 11 quarters.
  • UBS Group's Columbia Research Enhanced Value ETF position peaked at $104K in Q1 2026.
  • 37 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.